Efficacy and safety of radiotherapy combined with anti‐angiogenic therapy and immune checkpoint inhibitors in <scp>MSS</scp>/<scp>pMMR</scp> metastatic colorectal cancer

Menglan Zhai, Zixuan Zhang, Haihong Wang, Jinghua Ren, Sheng Zhang, Mingjie Li, Lichao Liu, Lisha Li, Lan Zhang, Xin Li, Tao� Zhang, Zhenyu LinCancer 2023 · DOI

TL;DR

This study investigates the efficacy of adding radiotherapy (RT) to anti-angiogenic therapy (TT) and immune checkpoint inhibitors (ICIs) for metastatic colorectal cancer (mCRC) patients with MSS/pMMR status. The findings suggest that this combination significantly improves progression-free survival (PFS) and overall survival (OS) with manageable toxicity, positioning RT as a valuable addition to existing treatments.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a significant health challenge, and while immunotherapy (IT) has shown promise, its effectiveness is largely limited to a small subset of patients with high microsatellite instability (MSI-H). The majority of patients, those with microsatellite stable (MSS) or mismatch repair proficient (pMMR) tumors, often do not respond well to IT alone. This lack of response is attributed to complex factors within the tumor microenvironment, including tumor neovascularization. Anti-angiogenic drugs, by targeting this neovascularization, can potentially improve the tumor microenvironment and enhance the efficacy of ICIs. While combinations of anti-angiogenic drugs and ICIs have shown some preliminary success, their optimal application, particularly with the addition of radiotherapy (RT), remains an open question. RT is known to induce immunogenic cell death and enhance anti-tumor immunity, suggesting it could further boost the efficacy of TT + IT in MSS/pMMR mCRC. This paper aims to explore whether adding RT to TT + IT can improve outcomes for these patients.

Methods

This study employed a retrospective analysis of data from patients with metastatic colorectal cancer (mCRC) who received anti-angiogenic targeted therapy (TT) and immunotherapy (IT) with or without radiotherapy (RT) after failing standard therapies. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included objective response rate (ORR) and disease control rate (DCR). Patient data was collected from January 2015 to September 2022. Tumor MMR/MSI status was determined through immunohistochemistry and PCR-based assays. Statistical analysis involved Kaplan-Meier methods for survival analysis, log-rank tests, and Cox regression models for identifying prognostic factors.

Datasets

The study utilized data from 4105 CRC patients diagnosed between January 2015 and September 2022 at the Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. From this cohort, 113 mCRC patients who received targeted drugs plus ICIs were identified. Ultimately, 82 patients (42 in the RT group and 40 in the NRT group) were included in the final analysis. No new benchmarks were introduced; the study relied on existing patient data.

Key Insights and Ideas

  • RT as a potent enhancer: The most striking insight is that adding RT to the TT + IT regimen significantly improves survival outcomes in MSS/pMMR mCRC patients. This suggests RT is not just an adjunct but a critical component for maximizing the benefit of these therapies.
  • Timing of RT matters: The study hints that RT administered sequentially or simultaneously with TT + IT might be more effective than RT given after TT + IT. This implies that RT's immunomodulatory effects are best leveraged when they can synergize with or prime the tumor microenvironment for the subsequent or concurrent TT + IT.
  • Manageable toxicity: A crucial finding is that the addition of RT did not substantially increase treatment-related adverse events (TRAEs). This addresses a key concern for oncologists considering RT in combination therapies, suggesting it can be integrated safely.
  • Independent prognostic factor: Multivariate analysis identified RT as an independent prognostic factor for both PFS and OS, underscoring its significance beyond patient characteristics or treatment intensity.

Key Results

  • Improved Survival: The RT group demonstrated a significantly longer median PFS (5.0 months vs. 3.6 months, p=0.04) and median OS (15.2 months vs. 7.2 months, p=0.01) compared to the NRT group. This translates to a 38% reduction in the risk of disease progression or death and a 50% reduction in the risk of death.
  • Enhanced Response Rates: The ORR was significantly higher in the RT group (21.4%) compared to the NRT group (5.0%, p=0.03). The DCR also showed a favorable trend in the RT group (83.3% vs. 65.0%, p=0.06).
  • Optimal RT Sequencing: Within the RT group, sequential/simultaneous RT with TT + IT showed superior PFS (7.1 months) compared to sequential RT after TT + IT (3.5 months, p=0.004).
  • Safety Profile: TRAEs were primarily related to the anti-angiogenic drugs and ICIs. Only one patient experienced RT-related radiation pneumonitis, which was manageable. No treatment-related deaths were reported.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single-center retrospective study: This limits the generalizability of the findings due to potential selection bias and a relatively small sample size.
  • Heterogeneity of treatment regimens: The variety of anti-angiogenic drugs, ICIs, and RT approaches (sites and timing) within the study groups makes direct comparisons challenging and may affect consistency.
  • Limited subgroup analysis for RT: Due to the small number of patients in the RT group, detailed subgroup analyses based on specific RT sites or doses were not feasible.

Future work should focus on:

  • Prospective studies: Designing prospective trials is crucial to confirm these findings and to precisely determine the optimal RT parameters (dose, fractionation, timing) and combinations with specific anti-angiogenic agents and ICIs.
  • Investigating RT mechanisms: Further research is needed to fully understand how RT enhances the immune response in this context and how to best leverage its immunomodulatory effects.
  • Defining optimal RT sequencing: Clarifying the ideal sequence and timing of RT in relation to TT + IT is essential for maximizing patient benefit.

Summary updated

Abstract

Compared with TT + IT, RT combined with TT + IT improved survival outcomes in MSS/pMMR mCRC patients, with manageable toxicity. RT sequential/simultaneous TT + IT treatment is expected to be the optimal strategy for MSS/PMMR mCRC.
BibTeX
@inproceedings{zhai2023efficacy,
  author = {Menglan Zhai and Zixuan Zhang and Haihong Wang and Jinghua Ren and Sheng Zhang and Mingjie Li and Lichao Liu and Lisha Li and Lan Zhang and Xin Li and Tao� Zhang and Zhenyu Lin},
  title = {{Efficacy and safety of radiotherapy combined with anti‐angiogenic therapy and immune checkpoint inhibitors in <scp>MSS</scp>/<scp>pMMR</scp> metastatic colorectal cancer}},
  booktitle = {Cancer},
  year = {2023},
  doi = {10.1002/cam4.6820},
}
Figure